The Effect of Semaglutide on Disordered Eating Behaviour in Type 2 Diabetic Patients

What this study is testing ClinicalTrials.gov NCT06243536 ↗

Description as written by the study sponsor.

The aim of this study is to evaluate the effect of glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide on disordered eating behaviour in patients with overweight and type 2 diabetes. The investigators will also evaluate serum concentrations of incretin hormones GLP-1 and glucose-dependent insulinotropic polypeptide (GIP), as well as glucose variability using continuous glucose monitoring (CGM) devices before and after semaglutide, and determine his influence on eating disorders. In this prospective study the investigators aim to recruit 60 patients with type 2 diabetes and randomize them based on the presence of a disordered eating behaviour diagnosed by a validated questionnaire (1:1). Patients with a disordered eating behaviour will further be randomized (1:1) to receive semaglutide. At baseline and after 12 weeks of semaglutide therapy, the investigators will reevaluate glucose variability over 14 days using a continuous glucose monitoring device (CGM). With this study the investigators will determine the impact of GLP-1 receptor agonist semaglutide on disordered eating behaviour in patients with overweight and type 2 diabetes. This study will contribute to the knowledge about the role of incretin hormones and glucose variability in eating disorders in this population of patients.

Treatments tested

• Semaglutide Drug

  Semaglutide will be administered through 12 weeks.

• standard of care also known as Metformin, Sulfonylureas, Sodium-glucose cotransporter-2 inhibitors, pioglitazone Drug

  Patients not assigned to receive semaglutide will receive standard of care.